IDiyas

For the Inventor, By the Inventor

Mystic, CT, United States of America

Christopher John Helal

LinkedIn
USPTO Granted Patents = 33 

 

 

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 96(Granted Patents)


Location History:

  • East Lyme, CT (US) (2008 - 2012)
  • Mystic, CT (US) (2013 - 2024)

Company Filing History:

goldMedal32 out of 4,455 
 
Pfizer Corporation
 patents
silverMedal1 out of 189 
 
Ge Healthcare Limited
 patents

Years Active: 2008-2025

Loading Chart...
Loading Chart...
Loading Chart...
33 patents (USPTO):Explore Patents
1. 12398119 - Piperazine azaspiro derivatives (2025-08-26),
2. 12049465 - Tricyclic compounds and their use as phosphodiesterase inhibitors (2024-07-30),
3. 11524954 - Piperazine azaspiro derivatives (2022-12-13),
4. 11472805 - Tricyclic compounds and their use as phosphodiesterase inhibitors (2022-10-18),
5. 11312713 - Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors (2022-04-26),
6. 11161844 - Cyclic substituted imidazo[4,5-c]quinoline derivatives (2021-11-02),
7. 10858373 - Heterocyclic spiro compounds as MAGL inhibitors (2020-12-08),
8. 10738063 - 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds (2020-08-11),
9. 10723711 - 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors (2020-07-28),
10. 10669279 - Imidazopyridazine compounds (2020-06-02),
11. 10626125 - 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors (2020-04-21),
12. 10428034 - 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors (2019-10-01),
13. 10329308 - 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors (2019-06-25),
14. 10323042 - 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds (2019-06-18),
15. 10131669 - Pyrazolopyrimidine compounds (2018-11-20),

Title: The Inventive Mind of Christopher John Helal

Introduction:

Christopher John Helal, a prolific inventor hailing from Mystic, CT (US), has made significant contributions to the field of pharmaceuticals through his innovative patents. With a total of 31 patents, his work has had a profound impact on the treatment of various disorders.

Latest Patents:

Two of Helal's latest patents showcase his ingenuity and commitment to advancing medical science. The first patent involves Piperazine azaspiro derivatives, which have shown promise in treating M4-mediated disorders such as Alzheimer's Disease, Parkinson's Disease, and schizophrenia. The second patent focuses on tricyclic compounds as phosphodiesterase inhibitors, opening up new possibilities in pharmaceutical treatments.

Career Highlights:

Having worked at esteemed companies like Pfizer Corporation and GE Healthcare Limited, Helal's career is marked by a dedication to pushing boundaries and exploring new frontiers in pharmaceutical research. His patents stand as a testament to his expertise and passion for innovation in the medical field.

Collaborations:

Throughout his career, Helal has collaborated with talented individuals such as Patrick Robert Verhoest and Thomas Allen Chappie. These partnerships have resulted in groundbreaking inventions that have the potential to improve the lives of countless individuals facing various health challenges.

Conclusion:

Christopher John Helal's inventive spirit and unwavering commitment to scientific progress have solidified his position as a respected figure in the world of pharmaceutical innovations. His patents not only reflect his creativity but also underscore his desire to make a meaningful difference in the realm of healthcare. With a track record of success and a passion for discovery, Helal continues to inspire future generations of inventors to dream big and pursue groundbreaking ideas.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…